{"nctId":"NCT01437111","briefTitle":"Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","startDateStruct":{"date":"2011-10-26","type":"ACTUAL"},"conditions":["Osteoporosis"],"count":200,"armGroups":[{"label":"Fosamax Plus","type":"EXPERIMENTAL","interventionNames":["Drug: MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet"]}],"interventions":[{"name":"MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet","otherNames":["Fosamax Plus 70/5600"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Man aged 50 or older, or a woman who is postmenopausal on day of signing informed consent or has been menopausal for at least one year\n* Meets bone mineral density (BMD) criteria\n* Agree to discontinue any osteoporosis drug treatment for duration of study\n\nExclusion Criteria:\n\n* Any contraindication to alendronate and vitamin D\n* Not ambulatory\n* Has received treatment with any anabolic steroid agent within the past 12 months, systemic glucocorticoids, for more than 2 weeks in the past 6 months, current use of immunosuppressants, fluoride treatment at a dose greater than 1 mg/day for more than 2 weeks within the past 3 months, treated with parathyroid hormone (PTH) for more than 2 weeks within the past 3 months, current use of chemotherapy or heparin, use of growth hormone for more than 2 weeks within the past 6 months, use of active hormonal vitamin D analogs in the past 2 months, current use of vitamin A \\>10,000 IU daily, current use of, lithium, or anti-convulsants including barbiturates, hydantoins, and carbamazepine, current use of calcium supplement in amount excess of 1500 mg daily, and/or current use of Vitamin D supplement\n* History of malignancy \\<5 years, except adequately treated basal cell or squamous cell skin cancer and in situ cervical cancer\n* One or more of the following concomitant conditions: Upper gastrointestinal (GI) disorders not adequately controlled; myocardial infarction, unstable angina, stroke and revascularization condition within 3 months; malabsorption syndrome; primary or secondary hyperparathyroidism not adequately treated; thyroid disease not adequately controlled; severe renal insufficiency; uncontrolled genitourinary, cardiovascular, hepatic, renal, endocrine, hematologic, neurological, psychiatric, or pulmonary diseases; uncontrolled hypertension; new onset diabetes (within 3 months), poorly controlled hyperglycemia, or hypoglycemia for any cause; evidence for metabolic bone disease other than osteoporosis; abnormal indices of calcium metabolism; and/or active renal stone disease\n* User of illicit recreational drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence\n* Heavy consumer of alcohol or alcohol containing products.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Serum 25-hydroxyvitamin D >=50 ng/mL at Week 26","description":"Serum samples to measure serum 25-hydroxyvitamin D \\[25(OH)D\\] will be collected at specific visits during the treatment phase of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline of Bone Resorption Marker of Serum Beta-CrossLaps at Week 26","description":"Serum samples for Beta-CrossLaps (Î²-CTx) will be collected at specific visits during the treatment phase of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.65","spread":"56.94"},{"groupId":"OG001","value":"-49.82","spread":"35.08"},{"groupId":"OG002","value":"-76.81","spread":"20.33"},{"groupId":"OG003","value":"-57.74","spread":"40.34"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":198},"commonTop":["Upper respiratory tract infection"]}}}